Gossamer Bio CEO Faheem Hasnain at BIO22 (J.T. MacMillan Photography)

Gos­samer stops en­roll­ment on BTK in­hibitor pro­gram, goes all in on PAH drug

Gos­samer Bio is stop­ping en­roll­ment on a Phase Ib/II tri­al of its BTK in­hibitor in CNS lym­phoma, it said in its an­nu­al re­port Fri­day morn­ing.

The San Diego-based biotech said, “​​Based up­on the ben­e­fit / risk pro­file ob­served to date and a pri­or­i­ti­za­tion of re­sources to sup­port the ser­a­lu­tinib pro­gram,” it de­cid­ed to stop en­rolling the tri­al of the BTK in­hibitor known as GB5121. Next, Gos­samer plans to dis­cuss the avail­able da­ta with the tri­al’s da­ta re­view com­mit­tee, an in­de­pen­dent pan­el of ex­perts, to fig­ure out next steps. The tri­al orig­i­nal­ly ex­pect­ed to en­roll around 160 pa­tients, ac­cord­ing to a fed­er­al clin­i­cal tri­als data­base.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.